Compass Therapeutics (NASDAQ:CMPX) Coverage Initiated by Analysts at LADENBURG THALM/SH SH

Equities research analysts at LADENBURG THALM/SH SH began coverage on shares of Compass Therapeutics (NASDAQ:CMPX) in a research report issued to clients and investors on Wednesday. The brokerage set a “buy” rating and a $5.00 price target on the stock. LADENBURG THALM/SH SH’s price objective would indicate a potential upside of 128.83% from the stock’s current price.

Several other research analysts have also weighed in on CMPX. D. Boral Capital reiterated a “buy” rating and set a $30.00 target price on shares of Compass Therapeutics in a report on Monday, April 27th. Stifel Nicolaus set a $6.00 price objective on Compass Therapeutics in a research report on Monday, June 1st. Citigroup restated a “market outperform” rating on shares of Compass Therapeutics in a report on Thursday, June 4th. Wall Street Zen cut shares of Compass Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, April 25th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Compass Therapeutics in a research report on Thursday, March 12th. One analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Compass Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $12.25.

Compass Therapeutics Price Performance

CMPX traded down $0.01 during mid-day trading on Wednesday, hitting $2.19. The stock had a trading volume of 185,090 shares, compared to its average volume of 5,127,127. The stock’s fifty day simple moving average is $2.33 and its 200-day simple moving average is $4.48. The firm has a market capitalization of $393.50 million, a price-to-earnings ratio of -5.30 and a beta of 0.89. Compass Therapeutics has a 1-year low of $1.61 and a 1-year high of $6.88.

Compass Therapeutics (NASDAQ:CMPX) last announced its quarterly earnings results on Tuesday, May 5th. The company reported ($0.10) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.10). As a group, research analysts expect that Compass Therapeutics will post -0.42 earnings per share for the current fiscal year.

Institutional Trading of Compass Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in CMPX. Suvretta Capital Management LLC lifted its position in shares of Compass Therapeutics by 97.2% in the third quarter. Suvretta Capital Management LLC now owns 14,101,159 shares of the company’s stock worth $49,354,000 after purchasing an additional 6,951,666 shares in the last quarter. Vivo Capital LLC grew its position in Compass Therapeutics by 57.9% in the third quarter. Vivo Capital LLC now owns 9,545,466 shares of the company’s stock valued at $33,409,000 after purchasing an additional 3,502,000 shares in the last quarter. BVF Inc. IL increased its stake in Compass Therapeutics by 63.5% in the 4th quarter. BVF Inc. IL now owns 7,764,842 shares of the company’s stock valued at $41,697,000 after buying an additional 3,014,842 shares during the last quarter. Balyasny Asset Management L.P. acquired a new stake in Compass Therapeutics in the 3rd quarter valued at $9,892,000. Finally, Braidwell LP bought a new stake in Compass Therapeutics during the 4th quarter worth about $14,965,000. 68.43% of the stock is currently owned by institutional investors and hedge funds.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc is a clinical?stage biotechnology company dedicated to the discovery and development of novel immuno?oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti?tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47?SIRP? pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.